Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (egfr)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring egfr mutations

HIGHLIGHTS

• who: Yuichiro Takeda from the Department of Respiratory Medicine, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo, Japan have published the paper: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations, in the Journal: (JOURNAL) of January/31,/2020
• what: This study investigated the clinical characteristics of EGFR-mutated lung patients harboring the T790M substitution resistant to EGFR-TKIs as well as the advantages of rebiopsy and liquid for these patients. For patients with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.